AI-generated analysis. Always verify with the original filing.
COMPASS Pathways plc reported fourth quarter and full-year 2025 financial results, including a Q4 net loss of $93.9 million ($1.00 per share) and full-year net loss of $287.9 million ($3.08 per share), driven by non-cash warrant liability adjustments. The company announced plans for an FDA meeting to confirm NDA submission strategy for COMP360 in TRD by Q4 2026 and initiation of a Phase 2b/3 PTSD trial.
Event Type
Disclosure
Mandatory
Variant
8-K
of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchan
Financial Statements and Exhibits. (d) Exhibits. The following exhibits are filed herewith: Exhibit No. Description 99.1 Press Release dated March 24, 2026 104
| Metric | Value | Basis |
|---|---|---|
| Research and development expenses | $29.90 | GAAP |
| Research and development expenses | $118.40 | GAAP |
| General and administrative expenses | $16.00 | GAAP |
| General and administrative expenses | $60.60 | GAAP |
| Net loss | $93.90 | GAAP |
| Net loss per share basic and diluted | $1.00 | GAAP |
| Net loss | $287.90 | GAAP |
| Net loss per share basic and diluted | $3.08 | GAAP |
Cash runway
sufficient to fund operating expenses and capital expenditures